Manhattan Scientifics Updates its Previous July 19th Press Release

Breakthrough Device for Detection of Cancer

July 22, 2019

Click here to view the printer friendly version of this press release

NEW YORK--Manhattan Scientifics clarifies that it continues to own 64 million shares of Imagion Biosystems Ltd (ASX: IBX). Neither MHTX nor its management have sold any MHTX or IBX shares and have no present intention to do so.

This clarification is published as a result of recent unusually large trading in both MHTX and IBX on July 18 and 19. MHTX traded 17.1M shares and IBX traded 153.5M shares during the two day period.

About Manhattan Scientifics

Manhattan Scientifics Inc. ( is focused on commercialization of disruptive technologies in the nano medicine space.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.